ANCA titers had similar rates of relapse as those receiving rituximab as a scheduled dose. However, this study was limited by the small sample size, and there were wide CIs for the effect size Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally rec ommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance. Methotrexate and azathioprine are equally